Techniques in Heidenhain pouch experiments

DeVito, Robert; Harkins, Henry N.

doi:10.1152/jappl.1959.14.1.138

Cited by 41 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The abdomen was entered through a left subcostal incision. A Heidenhain pouch was constructed from the corpus of the stomach in the manner employed in this laboratory (DeVito and Harkins, 1959;Condon and Harkins, 1962). The anterior and posterior vagus nerves were isolated at the region of the oesophageal hiatus and their gastric branches divided.…”

Section: Materials and Experimental Methodsmentioning

confidence: 99%

Selective vagal effects on the intestinal phase of gastric secretion

Middleton¹,

Kelly²,

Nyhus³

et al. 1965

Gut

View full text Add to dashboard Cite

Section: Materials and Experimental Methodsmentioning

confidence: 99%

Selective vagal effects on the intestinal phase of gastric secretion

Middleton¹,

Kelly²,

Nyhus³

et al. 1965

Gut

View full text Add to dashboard Cite

“…at ASPET Journals on May 9, 2018 jpet.aspetjournals.org (DeVito and Harkins, 1959) using a polyacetal fistula tube under anesthesia with pentobarbital. The postoperative animals were used for experiments at least 4 weeks after surgery.…”

Section: Antisecretory and Antiulcer Effects Of Cs-526 309mentioning

confidence: 99%

Pharmacological Profile of Novel Acid Pump Antagonist 7-(4-Fluorobenzyloxy)-2,3-dimethyl-1-{[(1 S,2 S)-2-methyl cyclopropyl]methyl}-1 H-pyrrolo[2,3-d]pyridazine (CS-526)

Ito¹,

Kinoshita²,

Tomizawa³

et al. 2007

The Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

The pharmacological profiles of the novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526) were investigated in terms of hog gastric H ϩ ,K ϩ -ATPase activity, gastric acid secretion, and acute gastroesophageal lesions in comparison with other proton pump inhibitors (PPIs). CS-526 inhibited H ϩ ,K ϩ -ATPase activity in a concentration-dependent manner, with an IC 50 value of 61 nM. The inhibitory effect of CS-526 on H ϩ ,K ϩ -ATPase activity was more potent than that of any of the other PPIs examined. The inhibitory mechanism of CS-526 on H ϩ ,K ϩ -ATPase was a competitive antagonism to the K ϩ binding site of H ϩ ,K ϩ -ATPase, and it was also a reversible inhibition. In pylorus-ligated rats, intraduodenal or oral administration of CS-526 inhibited gastric acid secretion in a dose-dependent manner, and the ID 50 values were 2.8 or 0.7 mg/kg, respectively. In Heidenhain pouch dogs, intrapouch administration of CS-526 inhibited histamine-stimulated gastric acid secretion in a dose-and retention time-dependent manner. In a reflux esophagitis model, intraduodenal and oral administration of CS-526 prevented esophageal lesions with ID 50 values of 5.4 and 1.9 mg/kg, respectively. Lansoprazole prevented esophagitis only by intraduodenal administration (ID 50 ϭ 2.2 mg/kg). Furthermore, CS-526 inhibited acute gastric mucosal lesions. These data demonstrate that the novel acid pump antagonist CS-526 has potent antisecretory and antiulcer effects. These findings indicate that CS-526 would have a curative effect on gastroesophageal reflux disease via its potent antisecretory and antiulcer actions.

show abstract

“…At least 8 weeks prior to the experiment, male Beagle dogs (18-20 kg) were equipped with a Heiden hain pouch, which was drained by means of a cannula [16]. The dogs were trained to stay in a Pavlov stand.…”

Section: Heidenhain Pouch Dogsmentioning

confidence: 99%

A Substituted Thieno[3.4-d]imidazole versus Substituted Benzimidazoles as H<sup>+</sup>, K<sup>+</sup>-ATPase Inhibitors

Herling¹,

Bickel²,

Lang³

et al. 1988

Pharmacology

View full text Add to dashboard Cite

S 3337, 2-(2-ethylaminobenzylsulfinyl)-5,6-dimethoxybenzimidazole, and S 1924, 2-(5-methyl-2-picolylsulfιnyl)-1H-thieno[3.4-d]imidazole, are members of new classes of H⁺, K⁺-ATPase inhibitors. Their effects on H⁺, K⁺-ATPase and ¹⁴C-aminopyrine uptake in gastric glands were studied as well as in vivo in pylorus-ligated rats, stomach-lumen-perfused rats and Heidenhain pouch dogs. Their inhibitory effects were compared with the effect of omeprazole. In pylorus-ligated rats the two compounds showed a similar effectiveness as omeprazole. In stomach-lumen-perfused rats and in particular in Heidenhain pouch dogs, S 3337 was clearly less effective than omeprazole, while S 1924 was similarly effective in all in vivo models and in the H⁺, K⁺-ATPase assay as omeprazole. The difference in potency between S 1924 and omeprazole on ¹⁴C-aminopyrine uptake in gastric glands can be explained by the lower pK_a value of S 1924 (3.4) than that of omeprazole (4.0). Additionally, this study shows that there was no correlation between the effects in rats, particularly in pylorus-ligated rats, and in dogs for the H+, K+-ATPase inhibitors tested. It is concluded from this study that substituted thieno[3.4-d]imidazoles represent a new class of potent gastric acid inhibitors.

show abstract

Techniques in Heidenhain pouch experiments

Cited by 41 publications

References 0 publications

Selective vagal effects on the intestinal phase of gastric secretion

Selective vagal effects on the intestinal phase of gastric secretion

Pharmacological Profile of Novel Acid Pump Antagonist 7-(4-Fluorobenzyloxy)-2,3-dimethyl-1-{[(1 S,2 S)-2-methyl cyclopropyl]methyl}-1 H-pyrrolo[2,3-d]pyridazine (CS-526)

A Substituted Thieno[3.4-d]imidazole versus Substituted Benzimidazoles as H<sup>+</sup>, K<sup>+</sup>-ATPase Inhibitors

Contact Info

Product

Resources

About